RENX vs. KOO, COG, INHC, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, and CRW
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.
Renalytix vs. Its Competitors
Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.
Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.
28.3% of Kooth shares are held by institutional investors. Comparatively, 25.6% of Renalytix shares are held by institutional investors. 30.8% of Kooth shares are held by insiders. Comparatively, 6.7% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Kooth has a net margin of 7.89% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Kooth's return on equity.
In the previous week, Kooth's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.
Kooth currently has a consensus target price of GBX 456.67, suggesting a potential upside of 198.47%. Given Kooth's stronger consensus rating and higher probable upside, equities analysts plainly believe Kooth is more favorable than Renalytix.
Kooth has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Summary
Kooth beats Renalytix on 11 of the 14 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
This page (LON:RENX) was last updated on 9/9/2025 by MarketBeat.com Staff
Free RENX Stock Alerts